Pfizer 향후 성장

Future 기준 점검 0/6

Pfizer 의 수익은 연간 3.2% 감소할 것으로 예상되는 반면, 연간 수익은 1% 로 증가할 것으로 예상됩니다. EPS는 연간 0.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 17.8% 로 예상됩니다.

핵심 정보

1.0%

이익 성장률

0.79%

EPS 성장률

Pharmaceuticals 이익 성장	11.9%
매출 성장률	-3.2%
향후 자기자본이익률	17.83%
애널리스트 커버리지	Good
마지막 업데이트	14 Oct 2025

최근 향후 성장 업데이트

Recent updates

It Looks Like Pfizer Inc.'s (NYSE:PFE) CEO May Expect Their Salary To Be Put Under The Microscope

Apr 17

Pfizer: Tasty 7% Yield

Apr 16

R&D And Savings Programs Will Strengthen Future Outlook

Apr 08 Focus on R&D productivity in 2025 may risk misalignment with market needs, impacting future revenue if new products underperform.

Oncology Integration And Phase III Trials Will Redefine Future

Apr 07 Pfizer's oncology focus strengthens its portfolio and future revenue through Seagen integration and promising R&D pipeline developments in oncology and vaccines.

Pfizer: Shares Stabilize At $25 As Institutions Begin To Load Up (Rating Upgrade)

Mar 28

Pfizer: Bulls Need To Check Out Its Graham P/E

Mar 22

Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency

Mar 20I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines

Pfizer: Undervalued Safe Haven In Risk-Off Market

Mar 11

Pfizer Remains A Good Pick For Dividend Investors

Mar 04

Market Still Lacking Some Conviction On Pfizer Inc. (NYSE:PFE)

Feb 28

Why Pfizer's Stock Price Isn't Reflecting Its True Value

Feb 19

Pfizer: 3 Key Risks That Warrant A Sell

Feb 12

Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down

Feb 04

These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively

Feb 04

Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider

Jan 28

Pfizer's (NYSE:PFE) Upcoming Dividend Will Be Larger Than Last Year's

Jan 13

Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy

Jan 13

Pfizer: One Of The Next Big AI Winners

Dec 30

Pfizer (NYSE:PFE) Is Paying Out A Larger Dividend Than Last Year

Dec 30

Pfizer: Time And Patience Ran Out (Rating Downgrade)

Dec 24

Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call

Dec 18

Pfizer's (NYSE:PFE) Dividend Will Be Increased To $0.43

Dec 16

Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns

Dec 11

Pfizer: Too Cheap To Ignore

Dec 05

이익 및 매출 성장 예측

NYSE:PFE - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	61,049	13,672	18,442	21,328	19
12/31/2026	62,522	13,325	18,171	21,591	22
12/31/2025	62,984	11,213	12,294	17,575	23
6/29/2025	63,833	10,728	12,438	15,188	N/A
3/30/2025	62,464	7,867	11,220	13,989	N/A
12/31/2024	63,627	8,020	9,835	12,744	N/A
9/29/2024	60,433	4,274	8,227	11,263	N/A
6/30/2024	56,224	-2,593	4,810	8,005	N/A
3/31/2024	55,947	-288	5,106	8,578	N/A
12/31/2023	59,554	2,134	4,793	8,700	N/A
10/1/2023	69,274	10,469	8,178	12,042	N/A
7/2/2023	78,420	21,494	10,665	14,560	N/A
4/2/2023	93,154	29,035	20,206	23,938	N/A
12/31/2022	101,175	31,366	26,031	29,267	N/A
10/2/2022	99,878	29,953	23,362	26,599	N/A
7/3/2022	101,275	29,481	28,440	31,454	N/A
4/3/2022	92,433	25,410	31,783	34,583	N/A
12/31/2021	81,288	22,413	29,869	32,580	N/A
10/3/2021	68,877	19,485	29,769	32,291	N/A
7/4/2021	55,119	12,236	21,141	23,552	N/A
4/4/2021	46,084	9,032	13,477	15,808	N/A
12/31/2020	41,651	6,630	12,177	14,403	N/A
9/27/2020	32,334	212	10,512	12,547	N/A
6/28/2020	34,737	6,977	12,777	14,967	N/A
3/29/2020	38,137	9,427	11,702	14,023	N/A
12/31/2019	40,905	10,707	10,542	12,588	N/A
9/29/2019	53,039	16,211	10,897	13,557	N/A
6/30/2019	53,656	12,638	11,746	14,306	N/A
3/31/2019	53,859	11,464	N/A	15,542	N/A
12/31/2018	40,825	3,824	N/A	15,827	N/A
9/30/2018	53,373	23,808	N/A	18,178	N/A
7/1/2018	53,244	22,545	N/A	17,808	N/A
4/1/2018	52,673	21,746	N/A	17,201	N/A
12/31/2017	52,546	21,305	N/A	16,802	N/A
10/1/2017	52,471	9,791	N/A	15,463	N/A
7/2/2017	52,347	8,308	N/A	15,311	N/A
4/2/2017	52,598	7,281	N/A	15,677	N/A
12/31/2016	52,824	7,198	N/A	16,192	N/A
10/2/2016	53,243	6,270	N/A	15,049	N/A
7/3/2016	52,286	7,036	N/A	15,332	N/A
4/3/2016	50,992	7,615	N/A	15,816	N/A
12/31/2015	48,851	6,948	N/A	14,688	N/A
9/27/2015	47,922	8,366	N/A	15,188	N/A
6/28/2015	48,196	8,913	N/A	14,631	N/A
3/29/2015	49,116	9,200	N/A	14,628	N/A
12/31/2014	49,605	9,085	N/A	17,084	N/A

애널리스트 향후 성장 전망

수입 대 저축률: PFE 의 연간 예상 수익 증가율(1%)이 saving rate(3.1%) 미만입니다.

수익 vs 시장: PFE 의 연간 수익(1%)이 US 시장(15.6%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: PFE 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: PFE 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -3.2%).

고성장 매출: PFE 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -3.2%).

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: PFE의 자본 수익률은 3년 후 17.8%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/10/15 17:52
종가	2025/10/15 00:00
수익	2025/06/29
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Pfizer Inc.는 45명의 분석가가 다루고 있습니다. 이 중 23명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
David Toung	Argus Research Company
Kerry Holford	Berenberg
Luisa Hector	Berenberg

Pfizer 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Pfizer Inc. Reaffirms Earnings Guidance for the Full Year of 2025

Pfizer Inc. Reaffirms Earnings Guidance for the Year 2025

Pfizer Inc. Provides Earnings Guidance for the Year 2025

Pfizer Inc. Provides Earnings Guidance for the Fiscal Year 2025; Reaffirms Earnings Guidance for the Year 2024

Pfizer Inc. Revises Earnings Guidance for the Year 2024

Recent updates

Pfizer: Don't Forget About Value During AI Frenzy

Pfizer Inc. Announces Positive Topline Results from the Phase 3 Her2climb-05 Trial of First-Line Combination Therapy with the Tyrosine Kinase Inhibitor Tukysa®?

Second quarter dividend of US$0.43 announced

Investor sentiment improves as stock rises 15%

Hearing Against Pfizer Set for 29 September in Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen by Levin Papantonio

Pfizer Inc. to Report Q3, 2025 Results on Nov 04, 2025

New major risk - Revenue and earnings growth

Pfizer Inc. (NYSE:PFE) agreed to acquire Metsera, Inc. (NasdaqGS:MTSR) from Arch Venture Partners, L.P., Population Health Partners, LLC and others for $5 billion.

Arbutus Pharma Corp. and Genevant Sciences GmbH Provides Lawsuit Update

Nastlaw LLC and Direct Purchaser Plaintiffs Announce Additional Settlements in Re Generic Pharmaceutical Pricing Antitrust Litigation

Pfizer Inc. and BioNTech SE Announce Topline Data Demonstrating Robust Immune Response with Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Olema Pharmaceuticals, Inc. Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

Enanta Pharmaceuticals, Inc. Files Patent Infringement Suit Against Pfizer Inc. in the Unified Patent Court of the European Union

Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business

PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Pfizer Inc. Reaffirms Earnings Guidance for the Full Year of 2025

BioNTech SE and Pfizer Inc. Announces Collaboration with Pfizer to Develop COVID-19 Vaccine, BNT162b2 mRNA Vaccine

Pfizer's 'Depo-Provera' Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control Pill

Upcoming dividend of US$0.43 per share

Pfizer Inc. and Astellas Pharma Inc. Announce Positive Topline Results from the Overall Survival (OS) Analysis from the Phase 3 EMBARK Study Evaluating XTANDI

First quarter dividend of US$0.43 announced

Pfizer Inc. Announces Positive Topline Phase 3 Results for Hympavzi™? in Hemophilia A or B with Inhibitors

Arvinas and Pfizer Announce Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Pfizer Inc. Announces Statically Significant and Clinically Significant Results from the Phase 3 BREAKWATER Trial Evaluating BRAFTOVI®? (Encorafenib) in Combination with Cetuximab and mFOLFOX6

Case Management Conference in the Depo-Provera Legal Action Against Pfizer Inc

Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2

Pfizer's Q1 Update May Mark A Bottom In The Stock

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Pfizer Inc. Reaffirms Earnings Guidance for the Year 2025

Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naive, High-Risk Non-Muscle Invasive Bladder Cancer

Fourth quarter dividend of US$0.43 announced

Pfizer Inc. Declares Second-Quarter 2025 Dividend, Payable on June 13, 2025

Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle

It Looks Like Pfizer Inc.'s (NYSE:PFE) CEO May Expect Their Salary To Be Put Under The Microscope

ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO to Include Adults Aged 50 to 59 At Increased Risk of Disease

Pfizer: Tasty 7% Yield

Pfizer Inc. Provides Update on Oral Glp-1 Receptor Agonist Danuglipron

R&D And Savings Programs Will Strengthen Future Outlook

Oncology Integration And Phase III Trials Will Redefine Future

Entwistle & Cappucci LLP Files Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc

European Commission Approves Pfizer's RSV Vaccine ABRYSVO to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease

Pfizer: Shares Stabilize At $25 As Institutions Begin To Load Up (Rating Upgrade)

Pfizer: Bulls Need To Check Out Its Graham P/E

Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency

Pfizer Inc. to Report Q1, 2025 Results on Apr 29, 2025

Pfizer Inc., Annual General Meeting, Apr 24, 2025

Arvinas, Inc. and Pfizer Inc. Announce Positive Topline Results from Phase 3 Veritac-2 Clinical Trial

Pfizer: Undervalued Safe Haven In Risk-Off Market​

Pfizer Remains A Good Pick For Dividend Investors

Market Still Lacking Some Conviction On Pfizer Inc. (NYSE:PFE)

Chairman of the Board & CEO exercised options and sold US$904k worth of stock

Insider exercised options and sold US$243k worth of stock

Why Pfizer's Stock Price Isn't Reflecting Its True Value

Pfizer’s TALZENNA in Combination with XTANDI Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer

U.S. FDA Approves Pfizer's ADCETRIS Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Pfizer: 3 Key Risks That Warrant A Sell

Pfizer Inc. and Astellas Pharma Inc.'s PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer

Pfizer Inc. Provides Earnings Guidance for the Year 2025

Full year 2024 earnings: EPS misses analyst expectations

Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down

These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively

Pfizer’s Braftovi Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 Breakwater Trial

Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider

Pfizer Inc. Announces Positive Results from the Phase 3 Breakwater Trial Evaluating Braftovi® (Encorafenib) in Combination with Cetuximab and Mfolfox6

Upcoming dividend of US$0.43 per share

Pfizer Intends to Sell Approximately 700 Million Ordinary Shares in Haleon

Pfizer's (NYSE:PFE) Upcoming Dividend Will Be Larger Than Last Year's

Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Pfizer: Undervalued Safe Haven In Risk-Off Market